C-Type Natriuretic Peptide (CNP) (1-22), human TFA
目录号 : GC63447
C-Type Natriuretic Peptide (CNP) (1-22)，人 TFA，通过结合利钠肽受体 B (NPR-B) 发挥其主要生物学效应，NPR-B 是一种膜结合鸟苷酸环化酶受体，可产生环磷酸鸟苷 (cGMP) .
Cas No.:1966153-17-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Animal experiment [2]: | |
|
Animal models |
Four-week-old female ddY mice |
|
Preparation Method |
Mice were separated into four groups: the untreated (baseline) group, the 2 mg/kg C-Type Natriuretic Peptide (CNP) group, the 1 mg/kg C-Type Natriuretic Peptide (CNP) group, and the vehicle (normal saline) group. C-Type Natriuretic Peptide (CNP) and vehicle were administered intravenously. |
|
Dosage form |
Intravenously injection, 1 or 2 mg/kg |
|
Applications |
In the pylorus and rectum, after 2 mg/kg C-Type Natriuretic Peptide (CNP) was administered, cGMP production was remarkably increased as early as 1 minute compared with that after 1 mg/kg C-Type Natriuretic Peptide (CNP) was administered |
|
References: [1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9. | |
C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM) [1].
C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice [2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action [3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying [1].
References:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616
C 型钠尿肽 (CNP) (1-22)，人 TFA，通过与钠尿肽受体 B (NPR-B) 结合发挥其主要生物学作用，NPR-B 是一种膜结合鸟苷酸环化酶受体，可产生环磷酸鸟苷（cGMP）。 C-Type Natriuretic Peptide (CNP) 是利钠肽受体 NPR-B 和 C（Kds = 7 和 10.8 pM）的选择性激动剂[1]。
C 型钠尿肽 (CNP) (1-22)，在使用胎鼠胫骨的器官培养实验中显着促进纵向骨生长 [2]。 C 型钠尿肽 (CNP) (1-22) 体内给药可能通过其抗纤维化和抗肥大作用减弱心肌梗死 (MI) 后的心脏重塑[3]。 CNP 给药后 NPR-B 介导的 cGMP 产生特异性作用于幽门、结肠和直肠，并有助于胃排空[1]。
| Cas No. | 1966153-17-2 | SDF | |
| 分子式 | C95H158F3N27O30S3 | 分子量 | 2311.62 |
| 溶解度 | Water : 2 mg/mL (0.87 mM; Need ultrasonic) | 储存条件 | -20°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4326 mL | 2.163 mL | 4.326 mL |
| 5 mM | 0.0865 mL | 0.4326 mL | 0.8652 mL |
| 10 mM | 0.0433 mL | 0.2163 mL | 0.4326 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。